IL248494A0 - Methods and compositions for the treatment of fat storage diseases - Google Patents

Methods and compositions for the treatment of fat storage diseases

Info

Publication number
IL248494A0
IL248494A0 IL248494A IL24849416A IL248494A0 IL 248494 A0 IL248494 A0 IL 248494A0 IL 248494 A IL248494 A IL 248494A IL 24849416 A IL24849416 A IL 24849416A IL 248494 A0 IL248494 A0 IL 248494A0
Authority
IL
Israel
Prior art keywords
compositions
treatment
methods
storage disorders
lipid storage
Prior art date
Application number
IL248494A
Other languages
English (en)
Hebrew (he)
Original Assignee
Neurotrope Bioscience
Icahn School Med Mount Sinai
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neurotrope Bioscience, Icahn School Med Mount Sinai filed Critical Neurotrope Bioscience
Publication of IL248494A0 publication Critical patent/IL248494A0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
IL248494A 2014-04-18 2016-10-25 Methods and compositions for the treatment of fat storage diseases IL248494A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461981473P 2014-04-18 2014-04-18
US201461987360P 2014-05-01 2014-05-01
PCT/US2015/025821 WO2015160851A1 (en) 2014-04-18 2015-04-14 Methods and compositions for treatment of lipid storage disorders

Publications (1)

Publication Number Publication Date
IL248494A0 true IL248494A0 (en) 2016-12-29

Family

ID=54321042

Family Applications (1)

Application Number Title Priority Date Filing Date
IL248494A IL248494A0 (en) 2014-04-18 2016-10-25 Methods and compositions for the treatment of fat storage diseases

Country Status (9)

Country Link
US (3) US9724328B2 (enExample)
EP (1) EP3131543A4 (enExample)
JP (1) JP2017511387A (enExample)
KR (1) KR20170031653A (enExample)
CN (1) CN107072982A (enExample)
CA (1) CA2946115A1 (enExample)
IL (1) IL248494A0 (enExample)
MX (1) MX2016013680A (enExample)
WO (1) WO2015160851A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018034318A1 (ja) 2016-08-18 2018-02-22 国立大学法人 奈良先端科学技術大学院大学 免疫調節剤
AU2019255739A1 (en) * 2018-04-20 2020-11-12 Biojiva Llc Stabilized polyunsaturated compounds and uses thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7256286B2 (en) 1999-11-30 2007-08-14 The Board Of Trustees Of The Leland Stanford Junior University Bryostatin analogues, synthetic methods and uses
JP2003515601A (ja) 1999-11-30 2003-05-07 ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティ ブリオスタチンアナログ、合成方法および使用
WO2004004641A2 (en) 2002-07-02 2004-01-15 Blanchette Rockefeller Neurosciences Institute PKC ACTIVATION AS A MEANS FOR ENHANCING sAPPα SECRETION AND IMPROVING COGNITION USING BRYOSTATIN TYPE COMPOUNDS
US8497385B2 (en) 2007-08-31 2013-07-30 The Board Of Trustees Of The Leland Stanford Junior University Bryostatin analogues, synthetic methods and uses
WO2009099563A2 (en) * 2008-02-05 2009-08-13 Blanchette Rockefeller Neurosciences Institute Combination of a nmda receptor channel blocker and a pkc activator for treatment of alzheimer's disease
CA2941035A1 (en) 2008-07-28 2010-02-04 Blanchette Rockefeller Neurosciences Institute Pkc-activating compounds for the treatment of neurodegenerative diseases
US20120156180A1 (en) * 2009-08-10 2012-06-21 The Board Of Trustees Of The University Of Illinois Compositions and methods for the treatment of krabbe and other neurodegenerative diseases
US10821079B2 (en) * 2011-11-13 2020-11-03 Cognitive Research Enterprises, Inc. PKC activators and combinations thereof
WO2015148975A1 (en) * 2014-03-27 2015-10-01 Alkon Daniel L Compositions and methods to treat niemann-pick disease

Also Published As

Publication number Publication date
EP3131543A4 (en) 2017-12-20
US20150297559A1 (en) 2015-10-22
KR20170031653A (ko) 2017-03-21
US20190201377A1 (en) 2019-07-04
CN107072982A (zh) 2017-08-18
CA2946115A1 (en) 2015-10-22
US9724328B2 (en) 2017-08-08
WO2015160851A1 (en) 2015-10-22
JP2017511387A (ja) 2017-04-20
EP3131543A1 (en) 2017-02-22
MX2016013680A (es) 2017-07-05
US20170172978A1 (en) 2017-06-22

Similar Documents

Publication Publication Date Title
ZA201901279B (en) Compositions and methods for treatment of neurological disorders
IL251066A0 (en) Preparations and methods for the treatment of metabolic disorders
ZA201700311B (en) Compositions and methods of use for treating metabolic disorders
IL246833A0 (en) New salts and their pharmaceutical preparations for the treatment of inflammatory disorders
EP3183005A4 (en) Methods and compositions for the treatment of metabolic disorders
GB201402070D0 (en) Pharmaceutical compositions for the treatment of inflammatory disorders
HUE055913T2 (hu) Módszerek és készítmények a glioblastoma diagnosztizálására és kezelésére
IL246779A0 (en) Methods for the treatment and prevention of kidney disorders and fatty liver disorders
SG11201702554QA (en) Compositions and methods for the treatment of multiple sclerosis
EP3142699A4 (en) Compositions and methods for treating metabolic disorders
SG11201704829QA (en) Methods and compositions for treating brain diseases
EP3142674A4 (en) Methods and compositions for treatment of macrophage-related disorders
PT3113774T (pt) Composições de grapiprant e métodos de utilização das mesmas
IL251736B (en) Methods and compositions for the treatment of radiation-related disorders
IL248494A0 (en) Methods and compositions for the treatment of fat storage diseases
IL252707B (en) Compositions and methods for treating diseases
IL248846A0 (en) Methods and preparations of dezotraline for the treatment of adhd
HK40066377A (zh) 治疗神经疾病的组合物和方法
HK1234656A1 (en) Methods and compositions for treatment of lipid storage disorders
GB201408738D0 (en) Components and methods for formulation of components
SG11201704282UA (en) Compositions and methods for the treatment of multiple sclerosis
GB201419559D0 (en) Therapeutic compositions and methods